Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 20. Curr Opin Pediatr. 2009 Jun;21(3):365-72. doi: 10.1097/MOP.0b013e32832b1111. Bone tumors: osteosarcoma and Ewing's sarcoma. Heare T(1), Hensley MA, Dell'Orfano S. Author information: (1)Musculoskeletal Tumor Program, Department of Orthopaedic Surgery, University of Colorado, The Children's Hospital, Denver, CO, USA. heare.travis@tchden.org PURPOSE OF REVIEW: Osteosarcoma and Ewing's sarcoma are the two most common primary malignant bone tumors in children and account for approximately 6% of all childhood malignancies. Treatment methods have seen significant advancements, particularly in regard to chemotherapy and limb-sparing surgery. These advancements have led to increased survival rate. With many long-term survivors, it is important to evaluate long-term patient outcomes following treatment, including function and health-related quality of life. We will review the current trends in treatment of these diseases, different reconstructive options available, and the methods and results for evaluating the long-term results. RECENT FINDINGS: There have been many improvements in the medical treatment of these tumors leading to increasing long-term survival. There have also been improvements in reconstructive techniques for the maintenance of functional extremities in these patients. Newer evaluation methods for both functional outcome and health-related quality of life measures that are more specific to children and adolescents are being developed and in use. SUMMARY: This report will provide an overview of the current treatment options and long-term complications in primary malignant bone tumors for the pediatrician caring for a child with these problems. DOI: 10.1097/MOP.0b013e32832b1111